# Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight

> **NCT04366622** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 32 (actual)

## Conditions studied

- Clinical Pharmacology

## Interventions

- **DRUG:** Riociguat (Adempas, BAY 63-2521)

## Key facts

- **NCT ID:** NCT04366622
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-14
- **Primary completion:** 2011-04-28
- **Final completion:** 2011-09-15
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04366622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04366622, "Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04366622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*